The effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapy

Basit Öğe Kaydı
dc.contributor.authorGul, Kanyilmaz
dc.contributor.authorMehmet, Koc
dc.contributor.authorMeryem, Aktan
dc.date.accessioned2024-02-23T14:02:30Z
dc.date.available2024-02-23T14:02:30Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractPurpose: To assess the efficacy of oral glutamine (Gin) supplementation on clinical and survival outcomes of patients with locally advanced non-small cell lung cancer (LA-NSCLC). Materials/methods: Between 2010 and 2014, 122 stage III NSCLC patients were retrospectively analyzed. All patients received curative intent chemoradiotherapy (CRT). Prophylactic oral Gln powder was applied at a dose of 10 g tid. Effect of oral Gln supplementation in the prevention of severe (>grade 2-3) acute radiation-induced esophagitis (ARE) and weight loss, and their relation with overall survival (OS) and disease-free survival (DFS) was measured. Results: Median follow-up was 13.14 months (range; 1.97-55.36). Fifty-six (46%) patients had received oral Gln. Severe ARE was significantly lower in GIn-supplemented group (30% vs 70%; p = 0.002). Glnfree patients demonstrated a higher weight loss (p = 0.0001). In multivariate analysis hemoglobin (hb) level (<12 g/dL; p = 0.01) and nodal stage (N3; p = 0.01) were poor prognostic factors that affect OS; Weight loss (p = 0.06) and Gln-free (p = 0.05) reached nearly significant levels that poorly affect OS. Similarly, nodal stage (N3, p = 0.014) and Gln-free (p = 0.035) were poor prognostic factors that affect DFS. Weight loss (>= 2%, p = 0.06) and hb level (<12 g/dL, p = 0.07) reached borderline significance that poorly affect DFS. Nodal stage (N3) was the only poor prognostic factor that affect OS and DFS in univariate analysis (p = 0.01, p = 0.009; respectively). Conclusion: Oral Gln supplementation.significantly reduces grade 2-3 esophagitis and weight loss and also no negative impact on tumor control and survival outcomes in patients with LA-NSCLC. (C) 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.en_US
dc.identifier.doi10.1016/j.clnu.2016.06.012
dc.identifier.endpage1028en_US
dc.identifier.issn0261-5614
dc.identifier.issn1532-1983
dc.identifier.issue4en_US
dc.identifier.pmid27373496en_US
dc.identifier.scopus2-s2.0-84978544266en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1022en_US
dc.identifier.urihttps://doi.org/10.1016/j.clnu.2016.06.012
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11738
dc.identifier.volume36en_US
dc.identifier.wosWOS:000404315200012en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofClinical Nutritionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGlutamineen_US
dc.subjectAcute Radiation-Induced Esophagitisen_US
dc.subjectWeight Lossen_US
dc.subjectSurvival Outcomesen_US
dc.titleThe effects of oral glutamine on clinical and survival outcomes of non-small cell lung cancer patients treated with chemoradiotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu